Omnicell Stock Forecast, Price & News

Omnicell (NASDAQ:OMCL) Frequently Asked Questions

Is Omnicell a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Omnicell stock.
View analyst ratings for Omnicell or view top-rated stocks.

How has Omnicell's stock price been impacted by COVID-19?

Omnicell's stock was trading at $77.41 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OMCL stock has increased by 128.9% and is now trading at $177.22.
View which stocks have been most impacted by COVID-19.

When is Omnicell's next earnings date?

Omnicell is scheduled to release its next quarterly earnings announcement on Monday, February 7th 2022.
View our earnings forecast for Omnicell.

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) announced its quarterly earnings data on Tuesday, November, 2nd. The company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.45. The firm earned $296.40 million during the quarter, compared to analysts' expectations of $283.82 million. Omnicell had a trailing twelve-month return on equity of 12.51% and a net margin of 7.50%. During the same period in the previous year, the company earned $0.40 EPS.
View Omnicell's earnings history.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell updated its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided earnings per share (EPS) guidance of $3.800-$3.850 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.730. The company issued revenue guidance of $1.13 billion-$1.13 billion, compared to the consensus revenue estimate of $1.11 billion.

What price target have analysts set for OMCL?

7 brokers have issued 1 year price objectives for Omnicell's shares. Their forecasts range from $95.00 to $211.00. On average, they expect Omnicell's share price to reach $169.50 in the next year. This suggests that the stock has a possible downside of 4.4%.
View analysts' price targets for Omnicell or view top-rated stocks among Wall Street analysts.

Who are Omnicell's key executives?

Omnicell's management team includes the following people:

• Randall A. Lipps, Chairman, President & Chief Executive Officer
• Randy Lipps, Chairman, President, CEO & Founder
• Bill Wingfield, Vice President-North America Service & Operations
• Peter J. Kuipers, Chief Financial Officer & Executive Vice President (LinkedIn Profile)
• Giri Chodavarapu, Chief Information Officer

What is Randall A. Lipps' approval rating as Omnicell's CEO?

150 employees have rated Omnicell CEO Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among Omnicell's employees.

Who are some of Omnicell's key competitors?

Some companies that are related to Omnicell include Cerner (CERN), Vocera Communications (VCRA), Allscripts Healthcare Solutions (MDRX), HealthStream (HSTM), Computer Programs and Systems (CPSI), Cortexyme (CRTX), Athena Technology Acquisition (ATHN) and Mirage Energy (MRGE).
View all of OMCL's competitors.

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Who are Omnicell's major shareholders?

Omnicell's stock is owned by a number of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (5.62%), Conestoga Capital Advisors LLC (3.46%), Macquarie Group Ltd. (2.57%), Neuberger Berman Group LLC (2.38%), Dimensional Fund Advisors LP (1.98%) and Geneva Capital Management LLC (2.00%). Company insiders that own Omnicell stock include Christine Marie Mellon, Dan S Johnston, James T Judson, Joanne B Bauer, Joseph Brian Spears, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann.
View institutional ownership trends for Omnicell.

Which institutional investors are selling Omnicell stock?

OMCL stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, ArrowMark Colorado Holdings LLC, Voloridge Investment Management LLC, Tributary Capital Management LLC, Dimensional Fund Advisors LP, Peregrine Capital Management LLC, West Coast Financial LLC, and Thrivent Financial for Lutherans. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, James T Judson, Joseph Brian Spears, Peter J Kuipers, Randall A Lipps, Robin Gene Seim, and Scott Peter Seidelmann.
View insider buying and selling activity for Omnicell or view top insider-selling stocks.

Which institutional investors are buying Omnicell stock?

OMCL stock was purchased by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Voya Investment Management LLC, Principal Financial Group Inc., Barclays PLC, Victory Capital Management Inc., Nordea Investment Management AB, CastleArk Alternatives LLC, and Ziegler Capital Management LLC.
View insider buying and selling activity for Omnicell or or view top insider-buying stocks.

How do I buy shares of Omnicell?

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $177.22.

How much money does Omnicell make?

Omnicell has a market capitalization of $7.79 billion and generates $892.21 million in revenue each year. The company earns $32.19 million in net income (profit) each year or $1.71 on an earnings per share basis.

How many employees does Omnicell have?

Omnicell employs 2,860 workers across the globe.

Does Omnicell have any subsidiaries?

The following companies are subsidiares of Omnicell: 340B Link Business, Aesynt, Aesynt B.V., Aesynt Holding B.V., Aesynt Holding Cooperatief U.A., Aesynt Pty Ltd., Aesynt S.r.l, Aruba S.r.l, Ateb Inc. , Health Robotics S.r.l., InPharmics, MTS Medication Technologies Inc., MTS Packing Systems Inc., Mach 4 Automatisierungs Technik GmbH, MedPak Holdings Inc., Omnicell (Beijing) Technology Co. Ltd., Omnicell GmbH, Omnicell International LLC, Omnicell Ltd., and Omnicell SAS.

When was Omnicell founded?

Omnicell was founded in 1992.

What is Omnicell's official website?

The official website for Omnicell is www.omnicell.com.

Where are Omnicell's headquarters?

Omnicell is headquartered at 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043.

How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at (650) 251-6100, via email at [email protected], or via fax at 847-596-3402.